Inclusion Criteria:

- Written informed consent must be obtained prior to any screening procedures

- Advanced solid tumors

- Agreement to remaining hospitalized

- ECOG performance status of 0 or 1

- Life expectancy of at least 3 months

- Pregnant women. Male and female patients of reproductive potential must agree to
employ an effective method of birth control

- Demonstrate the specific hematological /blood chemistry laboratory values

Exclusion Criteria:

- Receipt of any investigational compound within 28 days prior to the first dose of
study drug or failure to have recovered from the side effects of such prior therapy

- Receipt of other antineoplastic therapy, including chemo-, hormonal, immuno-, and
radiation therapy, within 28 days (with some exceptions)

- Patients with CNS and/or leptomeningeal disease metastases

- Presence or history of thromboembolic or cerebrovascular events

- Impaired cardiac function or clinically significant cardiac disease

- Malabsorption syndrome or uncontrolled gastrointestinal toxicities

- Patients known to be HIV- or HBV- or HCV- positive

- Patients with acute or chronic uncontrolled infection

- Patients who have undergone surgery with general anesthesia for any cause within 28
days prior to the first dose of study drug

- Patients who have been receiving anticoagulant therapy

- Receipt of any hematopoietic colony stimulating factor or blood transfusion within 14
days prior to the first dose of study drug

- Patients who have been administering concomitant medication which may prolong the QTc
interval

- Patients with interstitial pneumonia or pulmonary fibrosis proven on a chest CT scan

- Patients with a large volume of ascitic and/or pleural fluid which requires drainage

- Patients with any bone fractures

- Deemed otherwise unsuitable by the investigator

Other protocol-defined inclusion/exclusion criteria may apply